AMAG Pharmaceuticals Inc (NASDAQ:AMAG) (TREND ANALYSIS) acquisition of Cord Blood Registry a strong fit, says Leerink. Leerink believes the acquisition of Cord Blood Registry by AMAG Pharmaceuticals is a strong strategic fit and another step in its growth and diversification strategy. The firm reiterates its Outperform rating on AMAG and said its estimates and price target are under review due to account for the deal. :theflyonthewall.com
Stock Performance: Click here for a free comprehensive Trend Analysis Report
AMAG Pharmaceuticals Inc (NASDAQ:AMAG) stock is currently trading 4.93% below its 52-week-high, 296.6% above its 52-week-low. The 1-year stock price history is in the range of $17.79 – $74.21. AMAG Pharmaceuticals Inc (AMAG) has a price to earnings ratio of 12.97 versus Healthcare sector average of 26.64. AMAG stock price has outperformed the Nasdaq by 59%. The Biotechnology company is currently valued at $2.15 billion and its share price closed the last trading session at $70.555. The stock has a 50-day moving average of $67.23 and a 200-day moving average of $53.57.
AMAG Pharmaceuticals Inc (AMAG) current short interest stands at 6 million shares. It has increased by 4% from the same period of last month. Around 35% of the company’s shares, which are float, are short sold. With a 10-days average volume of 0.69 million shares, the number of days required to cover the short positions stand at 8.8 days.
The company is expected to announce next quarter earnings on August 04, at consensus estimate of $0.72. AMAG Pharmaceuticals Inc (AMAG) reported last quarter earnings on May 05. The Biotechnology company announced earnings per share of $1.11 against a consensus Street estimate of $1.04, beating the average estimate by $0.07. This corresponds to an increase of $1.37 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently six analysts that cover AMAG Pharmaceuticals Inc stock. Of those six, four have a Buy rating, two have a Hold rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $72.67.
A recent analyst activity consisted of Deutsche Bank who initiated their coverage on the stock with Hold rating on June 12. Deutsche Bank fixed their price target at $75. This corresponds to a 6.3% upside from the last closing price. On the date of report, the stock closed at $67.77.
Another research firm was JP Morgan who reiterated their Neutral stance on May 6. JP Morgan increased their price target on AMAG Pharmaceuticals Inc from $41 to $51. This translates to a 27.72% downside from the last closing price. On the date of report, the stock closed at $56.82.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.